ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Takeda Pharmaceutical and the manufacturing contractor IDT Biologika have agreed to shift capacity currently reserved at IDT for production of Takeda’s dengue vaccine to Johnson & Johnson’s single-shot COVID-19 vaccine. The companies have agreed to make the capacity, in Dessau, Germany, available for 3 months, after which it will return to manufacturing Takeda’s vaccine. AstraZeneca recently chose IDT as a producer of its COVID-19 vaccine.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X